Roche targets wet AMD with faricimab and its 16-week regimenTwin late-stage trials of Roche’s ophthalmology drug faricimab have hit the mark in “wet” age-related macular degeneration trial, Share XRoche targets wet AMD with faricimab and its 16-week regimenhttps://pharmaphorum.com/news/faricimab/
Roche set to file ophthalmology drug faricimab in DMERoche looks set to mount a challenge to Bayer’s ophthalmology drug Eylea in 2021 after its faricimab antibody Share XRoche set to file ophthalmology drug faricimab in DMEhttps://pharmaphorum.com/news/roche-set-to-file-ophthalmology-drug-faricimab-in-dme/
Novartis signs ophthalmology AI deal with RetinAINovartis has signed a multi-year agreement with RetinAI, which will see the companies work together to use artificial Share XNovartis signs ophthalmology AI deal with RetinAIhttps://pharmaphorum.com/news/novartis-signs-ophthalmology-ai-d/
Janssen adds Hemera’s AMD gene therapy to pipelineJohnson & Johnson’s pharma unit Janssen has bought rights to an investigational gene therapy for a severe form Share XJanssen adds Hemera’s AMD gene therapy to pipelinehttps://pharmaphorum.com/news/janssen-adds-hemeras-amd-gene-therapy-to-ophthalmology-pipeline/
Novartis taps smartpatient for app to support wet AMD patientsGerman digital health company smartpatient is adding a new section of its MyTherapy app providing information on wet Share XNovartis taps smartpatient for app to support wet AMD patientshttps://pharmaphorum.com/news/novartis-taps-smartpatient-for-app-to-support-wet-amd-patients/
FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilarNovartis/Genentech’s eye drug Lucentis could be the next big blockbuster to face competition from cheaper biosimilars after its Share XFDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilarhttps://pharmaphorum.com/news/novartis-lucentis-could-face-biosimilar-competition/
Novartis keeps a close eye on gene therapy with Vedere Bio buyAlready a major player in gene therapy, Novartis has swooped on US startup Vedere Bio in a $280 Share XNovartis keeps a close eye on gene therapy with Vedere Bio buyhttps://pharmaphorum.com/news/novartis-keeps-a-close-eye-on-gene-therapy-with-vedere-bio-buy/
SparingVision raises €44.5m for retinitis pigmentosa gene therapyFrench biotech SparingVision has raised 44.5 million euros ($52.7 million) to develop its gene therapy for a rare Share XSparingVision raises €44.5m for retinitis pigmentosa gene therapyhttps://pharmaphorum.com/news/sparingvision-raises-44-5-million-euros-for-retinitis-pigmentosa-gene-therapy/
Takeda to make $200m loss after Novartis’ dry-eye drug hits trouble in EuropeNovartis’ decision to withdraw a European filing for its dry-eye drug Xiidra is to have a knock-on effect on Takeda, causing Share XTakeda to make $200m loss after Novartis’ dry-eye drug hits trouble in Europehttps://pharmaphorum.com/news/takeda-to-make-200m-loss-after-novartis-dry-eye-drug-hits-trouble-in-europe/
